Universal Health Services, Inc. (UHS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Universal Health Services (UHS) CFO Steve Filton provided an operational update, noting a potential $50M-$100M impact on acute care from expiring enhanced subsidies, though an extension is possible. He emphasized the company's ability to adapt to revenue pressures, citing past agility during COVID, and highlighted pending Medicaid supplemental payment approvals (D.C., Florida, Texas) that could add $150M-$200M annually. Acute care is returning to a normalized 5-7% revenue growth, while the new Cedar Hill hospital, which incurred a $25M EBITDA loss in Q2 due to delayed CMS status, is expected to quickly improve post-approval. Labor costs have largely stabilized, and commercial rate increases are projected to moderate to 4-5%. The behavioral segment's volume growth remains constrained by labor vacancies, despite improving recruitment, supporting a 6-8% revenue growth target. M&A remains opportunistic, with acute care targets scarce and behavioral acquisitions often priced too high for current valuation.

Analysis

Universal Health Services (UHS) is navigating a complex policy environment with a clear strategy focused on operational execution and cost management. Management quantifies the potential negative impact from the expiration of enhanced subsidies at $50 million to $100 million for its acute care division, a figure they believe is often overestimated by the market. This headwind appears manageable and is potentially offset by significant pending tailwinds, including new and expanded Medicaid supplemental payment programs in D.C., Florida, and Texas, which could collectively contribute an additional $150 million to $200 million in annual revenue. Operationally, the core acute care business is stabilizing towards a normative same-store revenue growth model of 5-7%, while the new Cedar Hill hospital, which created a $25 million EBITDA drag in Q2 due to a temporary CMS certification delay, is poised for a rapid turnaround upon imminent approval and is expected to reach divisional margin averages within 24 months. On the cost side, wage inflation has moderated to a 3-4% range and physician fee pressures are leveling off, with the company proactively leveraging technology and AI to enhance revenue cycle efficiency and clinical productivity. The behavioral segment's growth remains constrained not by demand, but by labor availability; this supply-side tightness supports strong pricing power, with a sustainable 6-8% revenue growth target skewed towards price until hiring further improves. The company's M&A posture remains disciplined, finding acute care targets scarce and behavioral assets overvalued, reinforcing a focus on organic growth and operational efficiency.

Key Decisions for Investors

• Investors should weigh the specified $50M-$100M headwind from potential subsidy expiration against the more than offsetting $150M-$200M potential annual benefit from new Medicaid supplemental programs, suggesting policy risks may be fully priced in.
• Monitor for the announcement of CMS deemed status for the Cedar Hill hospital, as this is a near-term catalyst expected to reverse a $25M quarterly EBITDA loss and begin its contribution to growth.
• Focus on labor market data and company-specific hiring updates as the primary leading indicators for volume acceleration in the high-demand behavioral health segment, where labor availability is the main growth constraint.
• Given the disciplined M&A commentary, expect capital allocation to prioritize organic growth, de-novo projects, and operational efficiency initiatives over large, dilutive acquisitions in the current valuation environment.